Argenx
ARGX
#468
Rank
A$76.75 B
Marketcap
A$1,227
Share price
0.12%
Change (1 day)
25.10%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.40. In 2025 the company made an earnings per share (EPS) of A$29.86 an increase over its 2024 EPS that were of A$19.72.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-20.76%
2025A$29.8651.44%
2024A$19.72-369.77%
2023A-$7.31-60.46%
2022A-$18.4963.33%
2021A-$11.32-40.37%
2020A-$18.98183.47%
2019A-$6.70123.09%
2018A-$3.0054.93%
2017A-$1.9414.07%
2016A-$1.7013.05%
2015A-$1.50-36.34%
2014A-$2.36209.04%
2013A-$0.76-33.99%
2012A-$1.16185.59%
2011A-$0.41